Fidelity Investments’s Ascendis Pharma A/S ASND Stock Holding History

Fidelity Investments’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$887M	Sell	3,876,601 -276,710	-7%	-$62M	0.05%	330
2025 Q4	$886M	Sell	4,153,311 -318,422	-7%	-$65.8M	0.05%	331
2025 Q3	$889M	Sell	4,471,733 -59,991	-1%	-$11.2M	0.05%	321
2025 Q2	$782M	Sell	4,531,724 -141,219	-3%	-$23M	0.04%	343
2025 Q1	$728M	Sell	4,672,943 -55,704	-1%	-$7.96M	0.05%	326
2024 Q4	$651M	Sell	4,728,647 -179,199	-4%	-$23.6M	0.04%	381
2024 Q3	$733M	Sell	4,907,846 -14,709	-0.3%	-$1.99M	0.04%	358
2024 Q2	$671M	Sell	4,922,555 -15,906	-0.3%	-$2.16M	0.04%	350
2024 Q1	$747M	Sell	4,938,461 -175,908	-3%	-$25.1M	0.05%	339
2023 Q4	$644M	Sell	5,114,369 -21,913	-0.4%	-$2.18M	0.05%	344
2023 Q3	$481M	Sell	5,136,282 -4,523	-0.1%	-$423K	0.04%	407
2023 Q2	$459M	Sell	5,140,805 -11,360	-0.2%	-$989K	0.04%	443
2023 Q1	$552M	Sell	5,152,165 -76,905	-1%	-$8.8M	0.05%	375
2022 Q4	$639M	Sell	5,229,070 -49,795	-0.9%	-$5.78M	0.06%	305
2022 Q3	$545M	Sell	5,278,865 -14,255	-0.3%	-$1.35M	0.06%	326
2022 Q2	$492M	Sell	5,293,120 -61,636	-1%	-$5.81M	0.05%	383
2022 Q1	$628M	Sell	5,354,756 -1,187	-0%	-$137K	0.05%	369
2021 Q4	$721M	Sell	5,355,943 -34,156	-0.6%	-$5.08M	0.05%	331
2021 Q3	$859M	Buy	5,390,099 +7,162	+0.1%	+$980K	0.07%	269
2021 Q2	$708M	Buy	5,382,937 +7,924	+0.1%	+$1.06M	0.06%	334
2021 Q1	$693M	Buy	5,375,013 +33,404	+0.6%	+$5.08M	0.06%	315
2020 Q4	$891M	Buy	5,341,609 +57,110	+1%	+$9.44M	0.08%	241
2020 Q3	$816M	Buy	5,284,499 +485,916	+10%	+$69.8M	0.08%	216
2020 Q2	$710M	Buy	4,798,583 +24,620	+0.5%	+$3.38M	0.08%	227
2020 Q1	$538M	Buy	4,773,963 +9	+0%	+$1.17K	0.07%	249
2019 Q4	$664M	Buy	4,773,954 +19,434	+0.4%	+$2.16M	0.07%	250
2019 Q3	$458M	Buy	4,754,520 +61,814	+1%	+$6.9M	0.05%	330
2019 Q2	$540M	Sell	4,692,706 -1	-0%	-$120	0.06%	299
2019 Q1	$552M	Buy	4,692,707 +489,461	+12%	+$42.9M	0.07%	293
2018 Q4	$263M	Buy	4,203,246 +50,984	+1%	+$3.2M	0.04%	488
2018 Q3	$294M	Buy	4,152,262 +812,468	+24%	+$55.9M	0.03%	522
2018 Q2	$222M	Sell	3,339,794 -384,738	-10%	-$25.3M	0.03%	622
2018 Q1	$244M	Buy	3,724,532 +94,308	+3%	+$5.3M	0.03%	608
2017 Q4	$145M	Hold	3,630,224	–	–	0.02%	821
2017 Q3	$132M	Buy	3,630,224 +391,504	+12%	+$11.2M	0.02%	855
2017 Q2	$89.9M	Hold	3,238,720	–	–	0.01%	1030
2017 Q1	$90.7M	Buy	3,238,720 +86,188	+3%	+$2.18M	0.01%	1028
2016 Q4	$63.8M	Buy	3,152,532 +639,708	+25%	+$12.8M	0.01%	1189
2016 Q3	$50.5M	Hold	2,512,824	–	–	0.01%	1289
2016 Q2	$33.3M	Buy	2,512,824 +216,383	+9%	+$3.33M	﹤0.01%	1446
2016 Q1	$42.6M	Sell	2,296,441 -14,300	-0.6%	-$254K	0.01%	1319
2015 Q4	$42.3M	Buy	2,310,741 +1,045,347	+83%	+$18.3M	0.01%	1322
2015 Q3	$22.4M	Buy	1,265,394 +221,438	+21%	+$4.31M	﹤0.01%	1611
2015 Q2	$18.4M	Buy	1,043,956 +62,656	+6%	+$1.1M	﹤0.01%	1759
2015 Q1	$17M	Buy	+981,300	New	+$17.8M	﹤0.01%	1788

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments's ASND Position: Q1 2026 in Review

Fidelity Investments reduced its Ascendis Pharma A/S (ASND) stake by 6.7% in Q1 2026, selling an estimated $62M and leaving 3,876,601 shares worth $887M. The position accounts for 0.05% of the portfolio, ranked #330.

Fidelity Investments first reported a position in ASND in Q1 2015 and has held it in 45 quarters since. The position peaked at $891M in Q4 2020. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Fidelity Investments held 3,876,601 shares of Ascendis Pharma A/S worth $887M as of Q1 2026.
Fidelity Investments sold 276,710 Ascendis Pharma A/S shares in Q1 2026, an estimated $62M.
Ascendis Pharma A/S made up 0.05% of Fidelity Investments's portfolio in Q1 2026, its #330 holding.
Fidelity Investments first reported a position in Ascendis Pharma A/S in Q1 2015 and has held it in 45 quarters since.
Fidelity Investments's Ascendis Pharma A/S position peaked at $891M in Q4 2020.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.